

EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 66356209/10/11 Fax: 66370190 Email: enquiries@ebnl.org Site: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2016/S-2319

August 12, 2016

Dept. of Corporate Services
The Stock Exchange, Mumbai
1st floor, New Trading Ring, Rotunda Bldg
Phiroze Jeejebhoy Towers, Dalal Street
Fort, Mumbai – 400 001.
Fax No. 22723121 Email ID: corp.relations@bseindia.com

Dear Sir,

Ref: Company Code No. 524768
Sub: Dissemination of Financial Results

We are pleased to inform you that the Board has taken on record the Un-audited Financial Results of the Company for the quarter ended 30.06.2016, at the meeting of the Board of Directors of the Company, held on Friday, 12th August, 2016, at 2.00 pm.

The above results were reviewed by the audit committee of the Board of Directors.

We are filing the results online in .pdf and excel format alongwith the Limited Review.

Thanking you,



Yours faithfully,
For Emmessar Biotech & Nutrition Ltd




Compliance Officer
Attachment: As above.

EMMESSAR BIOTECH & NUTRITION LIMITED				
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016				
	Rs in Lakhs			
Particulars	Current 3 Months Ended 30.06.2016 Unaudited	Preceeding 3 months ended 31.03.2016 Audited	Corresponding Qtr ended 30.06.2015 Unaudited	Previous Year Ended 31.3.2016 Audited
PART I				
01. Income from Operations				
(a) Net Sales/Income from Operations (Net of Excise Duty)	105.16	51.24	108.81	197.44
(b) Other Operating Income	0.00	0.00	0.00	0.00
Total Income	105.16	51.24	108.81	197.44
02) Expenditure				
(a) Cost of material consumed	61.82	0.96	43.16	53.56
(b) Purchase of Stock-trade	6.21	0.00	5.48	5.48
(c) Change in Inventories of Finished goods	-71.11	52.61	-13.04	37.16
(d) Employee Benefit Expenses	9.08	8.55	7.69	31.10
(e) Depreciation & Amortisation of Assets	0.27	1.62	0.37	2.72
(f) Other Expenditure	77.20	2.37	51.11	69.04
(g) Expenditure (a to f)	83.47	66.11	94.77	199.06
03) Profit / (loss) from Operations before Other Income, Interest & Exceptional items(1 - 2)	21.69	-14.87	14.04	-1.62
04) Other Income	16.20	16.08	10.02	25.87
05) Profit / (loss) before Interest and Exceptional Items (3 + 4)	37.89	1.21	24.06	24.25
06) Interest	0.00	0.00	0.00	0.00
07) Profit / (loss) after Interest but before Exceptional Items (5 - 6)	37.89	1.21	24.06	24.25
08) Exceptional Items	0.00	0.00	0.00	-92.17
09) Profit / (loss) from Ordinary Activities Before Taxation (7 + 8)	37.89	1.21	24.06	-67.92
10) Tax Expense (Deferred Tax)	0.00	-21.39	0.00	-21.39
11) Net Profit / (loss) from Ordinary Activities after Taxation (9 - 10)	37.89	22.60	24.06	-46.53
12) Extraordinary Item (net of tax expense)	0.00	0.00	95.00	0.00
13) Net Profit / (loss) for the period (11-12)	37.89	22.60	-70.94	-46.53
14) Share of profit / (loss) of associates		0.00	0.00	0.00
15) Minority Interest		0.00	0.00	0.00
16) Net profit / (loss) for the period (13+14+15)	37.89	22.60	-70.94	-46.53
17) Paid-up Equity Share Capital (Face Value of the share)	499.61 10.00	499.61 10.00	499.61 10.00	499.61 10.00
18) Reserves excluding Revaluation Reserve as per Balance Sheet of previous actg year	0.00	0.00	0.00	0.00
19) Earning per Shares	0.76	0.45	-1.42	-0.93
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)				
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)	0.76	0.45	-1.42	-0.93



PART II				
A. PARTICULARS OF SHAREHOLDINGS				
1) Public Shareholding				
- No. of Shares	2106676	2020385	2106676	2020385
- Percentage of Shareholding	42.17	40.44	42.17	40.44
2) Promoters & Promoter Group Shareholding				
a) Pledged/Encumbered				
- No. of Shares	Nil	Nil	Nil	Nil
- Percentage of Shares(as% of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil
- Percentage of shares(as% of the total Share Capital of the Company)				
b) Non Encumbered				
- No. of Shares	2889424	2975715	2889424	2975715
- Percentage of Shares(as% of the total shareholding of the Promoter & Promoter Group)	100%	100%	100%	100%
- Percentage of shares(as% of the total Share Capital of the Company)	57.83	59.56	57.83	59.56
Particulars	Three months ended 30.06.2016			
B. INVESTORS COMPLAINTS				
Pending at the beginning of the quarter			Nil	
Received during the quarter			Nil	
Disposed of during the quarter			Nil	
Remaining unresolved at the end of the qtr			Nil	
<p>* The above results were reviewed by the Audit Committee of the Board of Directors.</p> <p>* The Statutory Auditors have carried out a Limited Review of the results for the quarter ended June 30, 2016</p> <p>* The above Un-Audited Results were taken on record at the meeting of the Board of Directors held on 12th August, 2016</p>				
Mumbai 12-Aug-16			 By order of the Board MSR Ayyangar Managing Director	

EMMESSAR BIOTECH & NUTRITION LIMITED

Quarter ended Segment wise Revenue Results and Capital Employed

[Rs. In Lakhs]


	Current 3 Months Ended 30.06.2016 Unaudited	Preceeding 3 months ended 31.03.2016 Audited	Corresponding Qtr ended 30.06.2015 Unaudited	Previous Year Ended 31.3.2016 Audited
1. Segment Revenue (Net Sales / Income)				
a. Healthcare	35.35	4.24	20.79	48.67
b. Fine Chemicals	69.81	47.00	88.02	148.77
c. Others	16.19	14.58	10.02	25.87
Total:	121.35	65.82	118.83	223.31
Less: Inter Segment Revenue	0	0.00	0.00	0.00
Net Sales / Income from Operations	121.35	65.82	118.83	223.31
2. Segment Results (Profit / Loss) before Tax and Interest				
a. Healthcare	20.76	1.72	12.48	31.23
b. Fine Chemicals	30.84	-6.60	21.75	23.94
c. Others	16.20	16.08	10.02	25.87
Total:	67.80	11.20	44.25	81.04
Less:				
Interest	0	0.00	0.00	0.00
Other Unallocable Expenditure net off Unallocable Income	29.91	9.99	20.19	56.79
Total Profit before Tax	37.89	1.21	24.06	24.25
3. Capital Employed (Segment Assets - Segment Liabilities)				
a. Healthcare	2.21	17.28	4.91	17.28
b. Fine Chemicals	28.89	34.78	79.45	34.78
c. Others	13.43	-16.94	-79.14	-16.94
- Total:	44.53	35.12	5.22	35.12

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on August 12, 2016

Mumbai
12-Aug-16

By order of the Board
MSR Ayyangar
Managing Director



Tel. : 2200 4465, 2206 7440
Fax : 91-22-2200 0649
E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

V. Sankar Aiyar & Co.
CHARTERED ACCOUNTANTS
2-C, Court Chambers
35, New Marine Lines
Mumbai - 400 020

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30Th JUNE 2016**

The Board of Directors
Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Emmessar Biotech & Nutrition Limited, for the quarter ended 30th June 2016. This statement is the responsibility of the Company's management and has been approved by the Board of Directors at its Meeting held on August 12, 2016. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Agreement and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatements.

**For V. Sankar Aiyar & Co.
Chartered Accountants
Firm Regn. No.109208W**

V. Mohan

**(V. Mohan)
Partner**

Membership No. 17748

Place: Mumbai

Date: August 12, 2016.